Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

References

• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. doi:10.1111/jdv.13854
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006
   PubMed Web of Science ®Google Scholar
• Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):21–29. doi:10.1007/s40257-021-00654-z
   PubMed Web of Science ®Google Scholar
• Rivera-Díaz R, Daudén E, Carrascosa JM, Cueva P, Puig L. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment. Dermatol Ther. 2023;13(3):673–688. doi:10.1007/s13555-022-00881-0
   Web of Science ®Google Scholar
• Choon SE, Lebwohl MG, Turki H, et al. Clinical Characteristics and outcomes of Generalized Pustular Psoriasis (GPP) flares. Dermatology. 2023;239:345–354. doi:10.1159/000529274
   PubMed Web of Science ®Google Scholar
• Javor J, Buc M, Bucová M. Autoinflammatory process in the pathogenesis of generalized pustular psoriasis and perspectives of its targeted therapy. Epidemiol Mikrobiol Imunol Cas Spol Pro Epidemiol Mikrobiol Ces Lek Spol JE Purkyne. 2021;70(3):199–207.
   Google Scholar
• Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645–1651. doi:10.1111/jdv.14949
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Camela E. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;1–18. doi:10.1080/14712598.2022.2089020
   Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023:1–16. doi:10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023;22(1):25–41. doi:10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Dave R, Alkeswani A. An overview of biologics for psoriasis. J Drugs Dermatol. 2021;20(11):1246–1247. doi:10.36849/jdd.6040
   PubMed Web of Science ®Google Scholar
• Baum P, Visvanathan S, Garcet S, et al. Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol. 2022;149(4):1402–1412. doi:10.1016/j.jaci.2021.09.035
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Ozawa A, Kawasima T, et al. Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res. 2003;295(Suppl 1):S43–54. doi:10.1007/s00403-002-0371-6
   PubMed Web of Science ®Google Scholar
• Megna M, Fornaro L, Potestio L, et al. Efficacy and safety of anti-TNF biosimilars for psoriasis in pediatric and geriatric populations: a 72-week real-life study. Psoriasis. 2022;12:199–204. doi:10.2147/PTT.S365493
   PubMed Web of Science ®Google Scholar
• Zangrilli A, Bavetta M, Bianchi L. Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation. Expert Opin Drug Saf. 2020;19(4):433–438. doi:10.1080/14740338.2020.1752659
   PubMed Web of Science ®Google Scholar
• Morita A, Yamazaki F, Matsuyama T, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label Phase 3 study. J Dermatol. 2018;45(12):1371–1380. doi:10.1111/1346-8138.14664
   PubMed Web of Science ®Google Scholar
• Zangrilli A, Papoutsaki M, Talamonti M, Chimenti S. Long-term efficacy of Adalimumab in generalized pustular psoriasis. J Dermatolog Treat. 2008;19(3):185–187. doi:10.1080/09546630701759587
   PubMed Web of Science ®Google Scholar
• Jordan J, Bieber T, Wilsmann-Theis D. Adalimumab: safe and successful in severe pustular psoriasis. J Eur Acad Dermatol Venereol. 2009;23(5):592–593. doi:10.1111/j.1468-3083.2008.02972.x
   PubMed Web of Science ®Google Scholar
• Kimura U, Kinoshita A, Sekigawa I, Takamori K, Suga Y. Successful treatment with Adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis. J Dermatol. 2012;39(12):1071–1072. doi:10.1111/j.1346-8138.2012.01563.x
   PubMed Web of Science ®Google Scholar
• Gkalpakiotis S, Arenberger P, Gkalpakioti P, et al. A case of acute generalized pustular psoriasis of von Zumbusch treated with Adalimumab. J Eur Acad Dermatol Venereol. 2015;29(10):2063–2064. doi:10.1111/jdv.12597
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Komine M, Karakawa M, Kishimoto M, Ohtsuki M. Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis. J Dermatol. 2017;44(2):202–204. doi:10.1111/1346-8138.13632
   PubMed Web of Science ®Google Scholar
• Du Y, Yan Q, Chen M, Dong Z, Wang F. Efficacy of Adalimumab in pediatric generalized pustular psoriasis: case series and literature review. J Dermatolog Treat. 2022;33(6):2862–2868. doi:10.1080/09546634.2022.2089327
   PubMed Web of Science ®Google Scholar
• Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatolog Treat. 2005;16(5–6):350–352. doi:10.1080/09546630500430604
   PubMed Web of Science ®Google Scholar
• Hansel K, Marietti R, Tramontana M, et al. Childhood generalized pustular psoriasis: successful long-term treatment with Adalimumab. Dermatol Ther. 2020;33(3):e13294. doi:10.1111/dth.13294
   PubMed Web of Science ®Google Scholar
• Kawakami H, Maeda T, Abe N, et al. Efficacy of Adalimumab and methotrexate combination therapy on generalized pustular psoriasis patients unresponsive to infliximab monotherapy due to anti-infliximab antibody development. J Dermatol. 2015;42(1):94–95. doi:10.1111/1346-8138.12704
   PubMed Web of Science ®Google Scholar
• Gallo E, Llamas-Velasco M, Daudén E, García-Diez A. Refractory generalized pustular psoriasis responsive to a combination of Adalimumab and Acitretin. Int J Dermatol. 2013;52(12):1610–1611. doi:10.1111/j.1365-4632.2012.05472.x
   PubMed Web of Science ®Google Scholar
• Kimura U, Kinoshita A, Haruna K, et al. Generalized pustular psoriasis-like eruptions induced after the first use of Adalimumab in the treatment of psoriatic arthritis. J Dermatol. 2012;39(3):286–287. doi:10.1111/j.1346-8138.2011.01344.x
   PubMed Web of Science ®Google Scholar
• Rallis E, Korfitis C, Stavropoulou E, Papaconstantis M. Onset of palmoplantar pustular psoriasis while on Adalimumab for psoriatic arthritis: a “class effect” of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction? J Dermatolog Treat. 2010;21(1):3–5. doi:10.3109/09546630902882089
   PubMed Web of Science ®Google Scholar
• Strober BE. The treatment of psoriasis with etanercept. Semin Cutan Med Surg. 2005;24(1):28–36. doi:10.1016/j.sder.2005.01.003
   PubMed Web of Science ®Google Scholar
• Esposito M, Mazzotta A, Casciello C, Chimenti S. Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series. Dermatology. 2008;216(4):355–360. doi:10.1159/000117706
   PubMed Web of Science ®Google Scholar
• Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle FO. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology. 2002;205(2):213–216. doi:10.1159/000063919
   PubMed Web of Science ®Google Scholar
• Ephrem G, Jour G, Smith BL. Successful treatment of von Zumbusch generalized pustular psoriasis with cyclosporine after eruption post etanercept injection. J Med Liban. 2011;59(3):168–169.
   PubMedGoogle Scholar
• Vine K, Votava HJ, Smith BL. Generalized pustular psoriasis of Zambusch: case report of successful disease control with cyclosporine and etanercept. Cutis. 2012;90(3):132–136.
   PubMed Web of Science ®Google Scholar
• Fialová J, Vojáčková N, Vaňousová D, Hercogová J. Juvenile generalized pustular psoriasis treated with etanercept. Dermatol Ther. 2014;27(2):105–108. doi:10.1111/dth.12065
   PubMed Web of Science ®Google Scholar
• Georgesen C, Wildman H, Wang X, Magro C. Pediatric pustular psoriasis responsive to cyclosporine bridged to etanercept: a treatment approach. Dermatol Online J. 2017;23(11):1. doi:10.5070/D32311037267
   Google Scholar
• Papoutsaki M, Osório F, Morais P, et al. Infliximab in psoriasis and psoriatic arthritis. BioDrugs. 2013;27(Suppl 1):13–23. doi:10.1007/BF03325638
   PubMedGoogle Scholar
• Torii H, Nakagawa H. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 2011;38(4):321–334. doi:10.1111/j.1346-8138.2010.00971.x
   PubMed Web of Science ®Google Scholar
• Torii H, Terui T, Matsukawa M, Takesaki K, Ohtsuki M, Nakagawa H. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: results from the prospective post-marketing surveillance. J Dermatol. 2016;43(7):767–778. doi:10.1111/1346-8138.13214
   PubMed Web of Science ®Google Scholar
• Samotij D, Gawron E, Szczęch J, Ostańska E, Reich A. Acrodermatitis continua of hallopeau evolving into generalized pustular psoriasis following COVID-19: a case report of a successful treatment with infliximab in combination with acitretin. Biologics. 2021;15:107–113. doi:10.2147/BTT.S302164
   PubMed Web of Science ®Google Scholar
• Ito M, Akutsu K, Isobe M, et al. Generalized pustular psoriasis complicated with idiopathic retroperitoneal fibrosis successfully treated with infliximab. J Dermatol. 2021;48(9):e436–e437. doi:10.1111/1346-8138.15974
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Moriya C, Shibuya Y, Kanoh H, Seishima M. Combination therapy of infliximab and granulocyte/monocyte adsorption apheresis for refractory pustular psoriasis with psoriatic arthritis. Acta Derm Venereol. 2013;93(3):364–365. doi:10.2340/00015555-1463
   PubMed Web of Science ®Google Scholar
• Smith N, Harms KL, Hines AC, et al. Acute treatment of generalized pustular psoriasis of von Zumbusch with single-dose infliximab. J Am Acad Dermatol. 2013;68(6):e187–9. doi:10.1016/j.jaad.2012.11.017
   PubMed Web of Science ®Google Scholar
• Sugiura K, Endo K, Akasaka T, Akiyama M. Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist. J Eur Acad Dermatol Venereol. 2015;29(10):2054–2056. doi:10.1111/jdv.12590
   PubMed Web of Science ®Google Scholar
• Saito K, Ito A, Ishikawa K, et al. Pustular psoriasis occurring after total colectomy for ulcerative colitis and relieved by administration of infliximab. J Dermatol. 2014;41(11):1033–1034. doi:10.1111/1346-8138.12629
   PubMed Web of Science ®Google Scholar
• Kim HS, You HS, Cho HH, et al. Two cases of generalized pustular psoriasis: successful treatment with infliximab. Ann Dermatol. 2014;26(6):787–788. doi:10.5021/ad.2014.26.6.787
   PubMed Web of Science ®Google Scholar
• Li M, Dai W, Yan W, Liu Y, Wang L, Li W. A dramatic response to a single dose of infliximab in a patient with prolonged pustular psoriasis derived from inverse psoriasis. Dermatol Ther. 2017;30(4):e12492. doi:10.1111/dth.12492
   Web of Science ®Google Scholar
• Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol. 2002;41(7):449–452. doi:10.1046/j.1365-4362.2002.01543.x
   PubMed Web of Science ®Google Scholar
• Elewski BE. Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol. 2002;47(5):796–797. doi:10.1067/mjd.2002.128382
   PubMed Web of Science ®Google Scholar
• Schmick K, Grabbe J. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab). Br J Dermatol. 2004;150(2):367. doi:10.1111/j.1365-2133.2004.05719.x
   PubMed Web of Science ®Google Scholar
• Benoit S, Toksoy A, Bröcker EB, Gillitzer R, Goebeler M. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol. 2004;150(5):1009–1012. doi:10.1111/j.1365-2133.2004.05960.x
   PubMed Web of Science ®Google Scholar
• Weishaupt C, Metze D, Luger TA, Ständer S. Treatment of pustular psoriasis with infliximab. J Ger Soc Dermatol JDDG. 2007;5(5):397–399. doi:10.1111/j.1610-0387.2007.06296.x
   PubMedGoogle Scholar
• Barland C, Kerdel FA. Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis. Arch Dermatol. 2003;139(7):949–950. doi:10.1001/archderm.139.7.949
   PubMedGoogle Scholar
• Routhouska SB, Sheth PB, Korman NJ. Long-term management of generalized pustular psoriasis with infliximab: case series. J Cutan Med Surg. 2008;12(4):184–188. doi:10.2310/7750.2008.07036
   PubMed Web of Science ®Google Scholar
• Adachi A, Komine M, Hirano T, et al. Case of generalized pustular psoriasis exacerbated during pregnancy, successfully treated with infliximab. J Dermatol. 2016;43(12):1439–1440. doi:10.1111/1346-8138.13429
   PubMed Web of Science ®Google Scholar
• Beksac B, Adisen E, Gurer MA. Treatment of generalized pustular psoriasis of pregnancy with infliximab. Cutis. 2021;107(3):E2–E5. doi:10.12788/cutis.0210
   PubMed Web of Science ®Google Scholar
• Babuna Kobaner G, Polat Ekinci A. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: report of a challenging case. Dermatol Ther. 2020;33(4):e13571. doi:10.1111/dth.13571
   PubMed Web of Science ®Google Scholar
• Sheth N, Greenblatt DT, Acland K, Barker J, Teixeira F. Generalized pustular psoriasis of pregnancy treated with infliximab. Clin Exp Dermatol. 2009;34(4):521–522. doi:10.1111/j.1365-2230.2008.02963.x
   PubMed Web of Science ®Google Scholar
• Lu J, Li Y, Yu N, Chen F, Ding Y, Yi X. Successful treatment of juvenile generalized pustular psoriasis with infliximab therapy: two case reports. J Int Med Res. 2020;48(3):300060520912091. doi:10.1177/0300060520912091
   PubMed Web of Science ®Google Scholar
• Tsang V, Dvorakova V, Enright F, Murphy M, Gleeson C. Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2016;30(11):e117–e119. doi:10.1111/jdv.13388
   PubMed Web of Science ®Google Scholar
• Skrabl-Baumgartner A, Weger W, Salmhofer W, Jahnel J. Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment. Pediatr Dermatol. 2015;32(1):e13–4. doi:10.1111/pde.12457
   PubMed Web of Science ®Google Scholar
• Pan J, Qiu L, Xiao T, Chen HD. Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab. Dermatol Ther. 2016;29(3):164–167. doi:10.1111/dth.12325
   PubMed Web of Science ®Google Scholar
• Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol. 2004;3(4):439–440.
   PubMedGoogle Scholar
• Martínez-Morán C, Sanz-Muñoz C, Morales-Callaghan AM, Torrero V, Miranda-Romero A. Pustular psoriasis induced by infliximab. J Eur Acad Dermatol Venereol. 2007;21(10):1424–1426. doi:10.1111/j.1468-3083.2007.02230.x
   PubMed Web of Science ®Google Scholar
• Pourciau C, Shwayder T. Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab. Pediatr Dermatol. 2010;27(5):539–540. doi:10.1111/j.1525-1470.2010.01267.x
   PubMed Web of Science ®Google Scholar
• Kato Y, Yamamoto T. Generalized pustular psoriasis triggered by infliximab in two patients with Crohn’s disease. J Dermatol. 2013;40(11):932–933. doi:10.1111/1346-8138.12268
   PubMed Web of Science ®Google Scholar
• Almutairi D, Sheasgreen C, Weizman A, Alavi A. Generalized pustular psoriasis induced by infliximab in a patient with inflammatory bowel disease. J Cutan Med Surg. 2018;22(5):507–510. doi:10.1177/1203475418758986
   PubMed Web of Science ®Google Scholar
• Zheng J, Gao Y, Ding Y. Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis. Dermatol Ther. 2019;32(6):e13132. doi:10.1111/dth.13132
   PubMed Web of Science ®Google Scholar
• Xia P, Li YH, Liu Z, et al. Recalcitrant paradoxical pustular psoriasis induced by infliximab: two case reports. World J Clin Cases. 2021;9(15):3655–3661. doi:10.12998/wjcc.v9.i15.3655
   PubMed Web of Science ®Google Scholar
• Strain J, Leis M, Lee KO, Fleming P. Certolizumab pegol in plaque psoriasis: considerations for pregnancy. Skin Therapy Lett. 2021;26(2):1–5.
   PubMedGoogle Scholar
• Okubo Y, Umezawa Y, Sakurai S, Hoshii N, Nakagawa H. Efficacy and safety of certolizumab pegol in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 52-week results. Dermatol Ther. 2022;12(6):1397–1415. doi:10.1007/s13555-022-00741-x
   PubMed Web of Science ®Google Scholar
• Yatsuzuka K, Matsumoto T, Sakane Y, et al. The use of certolizumab pegol to successfully treat generalized pustular psoriasis combined with psoriatic uveitis. J Dermatol. 2022. doi:10.1111/1346-8138.16704
   Google Scholar
• Mizutani Y, Mizutani YH, Matsuyama K, et al. Generalized pustular psoriasis in pregnancy, successfully treated with certolizumab pegol. J Dermatol. 2020;47(7):e262–e263. doi:10.1111/1346-8138.15355
   PubMed Web of Science ®Google Scholar
• Yiu ZZ, Warren RB. Ustekinumab for the treatment of psoriasis: an evidence update. Semin Cutan Med Surg. 2018;37(3):143–147. doi:10.12788/j.sder.2018.040
   PubMed Web of Science ®Google Scholar
• Daudén E, Santiago-et-Sánchez-Mateos D, Sotomayor-López E, García-Díez A. Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis. Br J Dermatol. 2010;163(6):1346–1347. doi:10.1111/j.1365-2133.2010.09995.x
   PubMed Web of Science ®Google Scholar
• Storan ER, O’Gorman SM, Markham T. Generalized pustular psoriasis treated with ustekinumab. Clin Exp Dermatol. 2016;41(6):689–690. doi:10.1111/ced.12868
   PubMed Web of Science ®Google Scholar
• Hay RAS, Pan JY. Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to Adalimumab therapy. Clin Exp Dermatol. 2014;39(6):751–752. doi:10.1111/ced.12392
   PubMed Web of Science ®Google Scholar
• Caca-Biljanovska N, V’lckova-Laskoska M, Laskoski D. Successful management of ustekinumab-induced pustular psoriasis without therapy discontinuation. Acta Dermatovenerol Croat. 2013;21(3):202–204.
   PubMed Web of Science ®Google Scholar
• Wenk KS, Claros JM, Ehrlich A. Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatolog Treat. 2012;23(3):212–214. doi:10.3109/09546634.2010.534430
   PubMed Web of Science ®Google Scholar
• Gregoriou S, Kazakos C, Christofidou E, Kontochristopoulos G, Vakis G, Rigopoulos D. Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol. 2011;21(1):104–105. doi:10.1684/ejd.2011.1164
   PubMed Web of Science ®Google Scholar
• Benzaquen M, Flachaire B, Rouby F, Berbis P, Guis S. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy. Rheumatol Int. 2018;38(7):1297–1299. doi:10.1007/s00296-018-4034-0
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35:e15667. doi:10.1111/dth.15667
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355–362. doi:10.1111/1346-8138.13622
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148–1155. doi:10.1111/jdv.12773
   PubMed Web of Science ®Google Scholar
• Okubo Y, Mabuchi T, Iwatsuki K, et al. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J). J Eur Acad Dermatol Venereol. 2019;33(2):325–332. doi:10.1111/jdv.15287
   PubMed Web of Science ®Google Scholar
• Egawa G, Honda T, Kabashima K. Long-term efficacy of ixekizumab in erythrodermic and generalized pustular psoriasis patients. J Eur Acad Dermatol Venereol. 2019;33(2):259. doi:10.1111/jdv.15416
   PubMed Web of Science ®Google Scholar
• Nagata M, Kamata M, Fukaya S, et al. Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab. J Am Acad Dermatol. 2020;82(3):758–761. doi:10.1016/j.jaad.2019.09.040
   PubMed Web of Science ®Google Scholar
• Morita A, Okubo Y, Morisaki Y, Torisu-Itakura H, Umezawa Y. Ixekizumab 80 mg every 2 weeks treatment beyond week 12 for Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis. Dermatol Ther. 2022;12(2):481–494. doi:10.1007/s13555-021-00666-x
   PubMed Web of Science ®Google Scholar
• Burlando M, Salvi I, Paravisi A, Cozzani E, Parodi A. Severe generalized pustular psoriasis successfully treated with ixekizumab: a case report. Case Rep Dermatol. 2022;14(3):326–329. doi:10.1159/000526037
   PubMed Web of Science ®Google Scholar
• Huang D, Liu T, Li J, Lu Y, Ma H. Generalized pustular psoriasis recurring during pregnancy and lactation successfully treated with ixekizumab. Dermatol Ther. 2022;35(12):e15878. doi:10.1111/dth.15878
   PubMed Web of Science ®Google Scholar
• Dattola A, Manfreda V, Esposito M, Bianchi L, Giunta A. A case of generalized pustular psoriasis and arthritis treated with ixekizumab. J Dermatolog Treat. 2020;31(7):754–755. doi:10.1080/09546634.2019.1606395
   PubMed Web of Science ®Google Scholar
• Megna M, Abategiovanni L, Annunziata A, et al. Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient. Dermatol Ther. 2022;35(5):e15382. doi:10.1111/dth.15382
   PubMed Web of Science ®Google Scholar
• Ito M, Kamata M, Uchida H, et al. Ixekizumab rapidly improves inflammatory markers in patients with generalized pustular psoriasis. Br J Dermatol. 2022;187(5):793–795. doi:10.1111/bjd.21701
   PubMed Web of Science ®Google Scholar
• Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016;15(10):1413–1420. doi:10.1080/14740338.2016.1221923
   PubMed Web of Science ®Google Scholar
• Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011–1017. doi:10.1111/1346-8138.13306
   PubMed Web of Science ®Google Scholar
• Böhner A, Roenneberg S, Eyerich K, Eberlein B, Biedermann T. Acute generalized pustular psoriasis treated with the IL-17A antibody secukinumab. JAMA Dermatol. 2016;152(4):482–484. doi:10.1001/jamadermatol.2015.4686
   PubMed Web of Science ®Google Scholar
• Reymundo A, Vilarrasa E, Baniandrés O, et al. Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice. J Eur Acad Dermatol Venereol. 2022;36(10):e849–e851. doi:10.1111/jdv.18317
   PubMed Web of Science ®Google Scholar
• Wu X, Yan T, Han C, et al. Rapid and sustained response of acute generalized pustular psoriasis of von Zumbusch to Secukinumab. J Eur Acad Dermatol Venereol. 2023;37(3):e338–e341. doi:10.1111/jdv.18609
   PubMed Web of Science ®Google Scholar
• Sun ZL, Liu ZL, Xu YY, Zhang XL, Zhang CL, Guan X. Successful treatment of generalized pustular psoriasis with secukinumab: a report of two cases. Chin Med J. 2020;133(24):3015–3016. doi:10.1097/CM9.0000000000001244
   PubMed Web of Science ®Google Scholar
• Akaji K, Nakagawa Y, Kakuda K, et al. Generalized pustular psoriasis associated with systemic lupus erythematosus successfully treated with secukinumab. J Dermatol. 2021;48(1):e43–e44. doi:10.1111/1346-8138.15645
   PubMed Web of Science ®Google Scholar
• Gabeff R, Safar R, Leducq S, et al. Successful therapy with secukinumab in a patient with generalized pustular psoriasis carrying homozygous IL36RN p.His32Arg mutation. Int J Dermatol. 2019;58(1):e16–e17. doi:10.1111/ijd.14293
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Atzori L, Lappi A, Pau M, Murgia S, Rongioletti F. Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2017;31(9):e420–e421. doi:10.1111/jdv.14234
   PubMed Web of Science ®Google Scholar
• Polesie S, Lidholm AG. Secukinumab in the treatment of generalized pustular psoriasis: a case report. Acta Derm Venereol. 2017;97(1):124–125. doi:10.2340/00015555-2467
   PubMed Web of Science ®Google Scholar
• Liu N, Zhu L, Cheng Y, Yu N, Yi X, Ding Y. Successful treatment of recurrent pustular psoriasis of pregnancy with secukinumab: a case report. Acta Derm Venereol. 2020;100(15):adv00251. doi:10.2340/00015555-3611
   PubMedGoogle Scholar
• Xue G, Lili M, Yimiao F, Miao W, Xiaohong Y, Dongmei W. Case report: successful treatment of acute generalized pustular psoriasis of puerperium with secukinumab. Front Med. 2022;9:1072039. doi:10.3389/fmed.2022.1072039
   Web of Science ®Google Scholar
• Ruan SF, Zhang LL, Liu Z, et al. Real-world data on the clinical use of secukinumab in pediatric generalized pustular psoriasis: a 48-week retrospective study. J Am Acad Dermatol. 2023;88(1):243–246. doi:10.1016/j.jaad.2022.04.064
   PubMed Web of Science ®Google Scholar
• Miao C, Chen Y, Wang Z, Xiang X, Liu Y, Xu Z. Real-world data on the use of secukinumab and Acitretin in pediatric generalized pustular psoriasis. J Dermatol. 2023;50(2):258–261. doi:10.1111/1346-8138.16551
   PubMed Web of Science ®Google Scholar
• Zhu H, Song P, Du D, Tian H. Successful treatment of a 3-year-old girl with generalized pustular psoriasis using secukinumab monotherapy. Pediatr Dermatol. 2021;38(5):1366–1367. doi:10.1111/pde.14795
   PubMed Web of Science ®Google Scholar
• Nishida M, Takeichi T, Kono M, et al. Successful secukinumab treatment of recalcitrant juvenile generalized pustular psoriasis. J Dermatol. 2020;47(3):e77–e78. doi:10.1111/1346-8138.15228
   PubMed Web of Science ®Google Scholar
• Guevara BEK, Aquino JMRM, Diaz RBS, et al. Infantile generalized pustular psoriasis with excellent response to secukinumab: a case report. Exp Dermatol. 2023. doi:10.1111/exd.14784
   PubMed Web of Science ®Google Scholar
• López-Sánchez C, Falla LM, Roé-Crespo E, et al. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis. J Dermatol. 2021;48(6):907–910. doi:10.1111/1346-8138.15673
   PubMed Web of Science ®Google Scholar
• Albela H, Begum S, Leong KF. Successful treatment of paediatric generalized pustular psoriasis with secukinumab: a case series. J Dermatolog Treat. 2022;33(3):1769–1773. doi:10.1080/09546634.2021.1899111
   PubMed Web of Science ®Google Scholar
• Dogra S, Bishnoi A, Narang T, Handa S. Secukinumab-induced paradoxical pustular psoriasis. Clin Exp Dermatol. 2019;44(1):72–73. doi:10.1111/ced.13731
   PubMed Web of Science ®Google Scholar
• Abbruzzese A, Venerito V, Lopalco G, Fornaro M, Giannotta M, Iannone F. Paradoxical pustular psoriasis in a patient with psoriatic arthritis on secukinumab treatment. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2020;26(6):e208–e209. doi:10.1097/RHU.0000000000001076
   Google Scholar
• Iznardo H, Puig L. The safety of brodalumab for the treatment of psoriasis. Expert Opin Drug Saf. 2020;19(4):365–372. doi:10.1080/14740338.2020.1730326
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, Ootaki K. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741–751. doi:10.1111/bjd.14702
   PubMed Web of Science ®Google Scholar
• Khemis A, Cavalié M, Montaudié H, Lacour JP, Passeron T. Rebound pustular psoriasis after brodalumab discontinuation. Br J Dermatol. 2016;175(5):1065–1066. doi:10.1111/bjd.14627
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis. 2022;12:127–137. doi:10.2147/PTT.S367744
   PubMed Web of Science ®Google Scholar
• Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab. J Cosmet Dermatol. 2023;22(3):1146–1148. doi:10.1111/jocd.15543
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023;1–8. doi:10.1080/14740338.2023.2218086
   Web of Science ®Google Scholar
• Shukuin R, Koizumi H, Ebata A, et al. Successful combination therapy of bimekizumab and granulocyte monocyte adsorption apheresis for generalized pustular psoriasis complicated with microscopic polyangiitis. J Dermatol. 2023;50. doi:10.1111/1346-8138.16707
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;1–18. doi:10.1080/09546634.2022.2036674
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis. 2022;12:205–212. doi:10.2147/PTT.S372262
   PubMed Web of Science ®Google Scholar
• Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022:1–8. doi:10.1080/09546634.2022.2081655
   PubMed Web of Science ®Google Scholar
• Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529–539. doi:10.1111/1346-8138.14294
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. doi:10.1080/14740338.2022.2160447
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34:e15030. doi:10.1111/dth.15030
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study. Clin Cosmet Investig Dermatol. 2023;16:529–536. doi:10.2147/CCID.S402183
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. doi:10.1111/dth.15524
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L. Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study. J Clin Med. 2023;12(9):3233. doi:10.3390/jcm12093233
   PubMed Web of Science ®Google Scholar
• Yamanaka K, Okubo Y, Yasuda I, Saito N, Messina I, Morita A. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study. J Dermatol. 2023;50(2):195–202. doi:10.1111/1346-8138.16667
   PubMed Web of Science ®Google Scholar
• Pavia G, Gargiulo L, Spinelli F, et al. Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab. J Eur Acad Dermatol Venereol. 2022;36(7):e502–e505. doi:10.1111/jdv.18032
   PubMed Web of Science ®Google Scholar
• Heyer S, Seiringer P, Eyerich S, et al. Acute generalized pustular psoriasis successfully treated with the IL-23p19 antibody risankizumab. J Ger Soc Dermatol JDDG. 2022;20(10):1362–1364. doi:10.1111/ddg.14857
   Web of Science ®Google Scholar
• McFeely O, Pender E, Victory L, Almutlaq H, Storan E. Risankizumab-induced paradoxical pustular psoriasis. Clin Exp Dermatol. 2022;47(3):616–617. doi:10.1111/ced.15006
   PubMed Web of Science ®Google Scholar
• Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109–120. doi:10.1016/j.jaci.2016.08.056
   PubMed Web of Science ®Google Scholar
• Blair HA. Spesolimab: first approval. Drugs. 2022;82(17):1681–1686. doi:10.1007/s40265-022-01801-4
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431–2440. doi:10.1056/NEJMoa2111563
   PubMed Web of Science ®Google Scholar
• Morita A, Choon SE, Bachelez H, et al. Design of effisayilTM 2: a randomized, double-blind, placebo-controlled study of spesolimab in preventing flares in patients with generalized pustular psoriasis. Dermatol Ther. 2023;13(1):347–359. doi:10.1007/s13555-022-00835-6
   Web of Science ®Google Scholar
• Müller VL, Kreuter A. [Remission of recalcitrant generalized pustular psoriasis under interleukin-36 receptor inhibitor spesolimab]. Dermatologie. 2023:1–4. German. doi:10.1007/s00105-023-05140-7
   Google Scholar
• Ran D, Yang B, Sun L, et al. Rapid and sustained response to Spesolimab in five Chinese patients with generalized pustular psoriasis. Clin Exp Dermatol. 2023. doi:10.1093/ced/llad108
   PubMed Web of Science ®Google Scholar
• Marasca C, Fornaro L, Martora F, Picone V, Fabbrocini G, Megna M. Onset of vitiligo in a psoriasis patient on ixekizumab. Dermatol Ther. 2021;34(5):e15102. doi:10.1111/dth.15102
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M. Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. Clin Cosmet Investig Dermatol. 2022;15:1649–1658. doi:10.2147/CCID.S364640
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;1–16. doi:10.1080/13543784.2023.2219387
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47:2280–2282. doi:10.1111/ced.15336
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Battista T, et al. Immune response to Covid-19 mRNA vaccination in psoriasis patients undergoing treatment with biologics. Clin Exp Dermatol. 2022;47:2310–2312. doi:10.1111/ced.15395
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Villani A, Tajani A, Fabbrocini G, Potestio L. Teledermatology: a useful tool also after COVID-19 era? J Cosmet Dermatol. 2022;21(6):2309–2310. doi:10.1111/jocd.14938
   PubMed Web of Science ®Google Scholar
• De Lucia M, Potestio L, Costanzo L, Fabbrocini G, Gallo L. Scabies outbreak during COVID-19: an Italian experience. Int J Dermatol. 2021;60(10):1307–1308. doi:10.1111/ijd.15809
   PubMed Web of Science ®Google Scholar
• Marasca C, Annunziata MC, Camela E, et al. Teledermatology and inflammatory skin conditions during COVID-19 era: new perspectives and applications. J Clin Med. 2022;11(6):1511. doi:10.3390/jcm11061511
   PubMed Web of Science ®Google Scholar
• Bellinato F, Gisondi P, Marzano AV, et al. Characteristics of patients experiencing a flare of generalized pustular psoriasis: a multicenter observational study. Vaccines. 2023;11(4):740. doi:10.3390/vaccines11040740
   Web of Science ®Google Scholar
• Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines. 2021;9(10):1482. doi:10.3390/biomedicines9101482
   PubMed Web of Science ®Google Scholar
• Young KZ, Sarkar MK, Gudjonsson JE. Pathophysiology of generalized pustular psoriasis. Exp Dermatol. 2023. doi:10.1111/exd.14768
   Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;1–3. doi:10.1080/14712598.2022.2113872
   Web of Science ®Google Scholar
• Kodali N, Blanchard I, Kunamneni S, Lebwohl MG. Current management of generalized pustular psoriasis. Exp Dermatol. 2023. doi:10.1111/exd.14765
   PubMed Web of Science ®Google Scholar